MARKET

ITCI

ITCI

Intra Cellular
NASDAQ
42.70
-0.81
-1.86%
After Hours: 42.70 0 0.00% 16:33 09/26 EDT
OPEN
42.63
PREV CLOSE
43.51
HIGH
44.59
LOW
42.43
VOLUME
601.34K
TURNOVER
0
52 WEEK HIGH
66.00
52 WEEK LOW
34.43
MARKET CAP
4.03B
P/E (TTM)
-11.5565
1D
5D
1M
3M
1Y
5Y
Insider Sell: Intra-Cellular Therapies
Insider Sell: Intra-Cellular Therapies
MT Newswires · 22h ago
Looking Into Intra-Cellular Therapies's Return On Capital Employed
Intra-Cellular Therapies (NASDAQ:ITCI) brought in sales totaling $55.58 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 20.08%, resulting in a loss of $86.60 million.
Benzinga · 09/02 14:25
Intra-Cellular cut to Neutral at Goldman on trends for antipsychotic drug
Goldman Sachs downgraded commercial-stage biopharma Intra-Cellular Therapies, Inc. (NASDAQ:<a href="https://seekingalpha.com/symbol/ITCI?utm_medium=referral&utm_source=webull.com" title="Intra-Cellular The...
Seekingalpha · 08/22 16:07
Benzinga's Top Ratings Upgrades, Downgrades For August 22, 2022
Upgrades
Benzinga · 08/22 14:03
Goldman Sachs Downgrades Intra-Cellular Therapies to Neutral, Lowers Price Target to $49
Goldman Sachs analyst Corinne Jenkins downgrades Intra-Cellular Therapies (NASDAQ:ITCI) from Buy to Neutral and lowers the price target from $64 to $49.
Benzinga · 08/22 09:05
--Mizuho Securities Adjusts Intra-Cellular Therapies' Price Target to $72 From $75, Keeps Buy Rating
--Mizuho Securities Adjusts Intra-Cellular Therapies' Price Target to $72 From $75, Keeps Buy Rating
MT Newswires · 08/11 11:39
--Needham Adjusts Intra-Cellular Therapies' Price Target to $67 from $65, Keeps Buy Rating
--Needham Adjusts Intra-Cellular Therapies' Price Target to $67 from $65, Keeps Buy Rating
MT Newswires · 08/10 11:55
--Goldman Sachs Lowers Intra-Cellular Therapies' Price Target to $64 From $71, Maintains Buy Rating
--Goldman Sachs Lowers Intra-Cellular Therapies' Price Target to $64 From $71, Maintains Buy Rating
MT Newswires · 08/10 10:34
More
About ITCI
Intra-Cellular Therapies, Inc. is a biopharmaceutical company. The Company is focused on the discovery, clinical development and commercialization of small molecule drugs that address underserved medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company provides CAPLYTA (lumateperone) for the treatment of schizophrenia in adults. The CAPLYTA is a prescription medicine used to treat the depressive episodes in adults with bipolar I or II, that can be taken alone or with lithium or valproate. The Company's pipeline is focused on three platforms: lumateperone and follow-on compounds, a phosphodiesterase 1 (PDE1) inhibitor platform and discovery platform which includes ITI-333 a novel compound with high affinity at serotonin 5-HT2A, dopamine D1 and mu opioid (MOP) receptors. The Company’s subsidiaries are ITI, Inc. (ITI) and ITI Limited.

Webull offers kinds of Intra-Cellular Therapies Inc stock information, including NASDAQ:ITCI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ITCI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ITCI stock methods without spending real money on the virtual paper trading platform.